AlphAIAlphAI — Financial news for AI agents
fool.comSEP 292 min read$TMDX

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?

TransMedics Group (TMDX) Director David Weill bought 1,336 shares on Sept. 11, 2026, at an average price of $81.63, increasing his stake to 16,392 shares. The company, which focuses on organ transplant technology, has a market cap of $2.7B and TTM revenue of $668.5M. TMDX stock has seen a one-year return of -30%.

Original reporting
fool.com
Published Sep 29, 2026, 4:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 6:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too? — source image
Source · fool.com
Decision brief

The 30-second read

$TMDXNeutralLow
01

Why it matters

The insider purchase is a modest confidence signal but unlikely to move the stock materially.

02

Market read

Minor insider activity with limited trading relevance.

03

What to watch

Potential upcoming regulatory or clinical trial news could change the relevance of this purchase.

Relevance 4/10Novelty 4/10Timing: post‑market, not time‑critical

Background

TransMedics Group develops the Organ Care System for donor organ preservation.

Company-level read

Ticker impact

$TMDXNeutralLow confidence
Context

Director David Weill bought 1,336 shares (~$109k) of TransMedics Group, increasing his stake to 16,392 shares.

Expected impact

slight upward pressure as investors view the buy as a positive signal

Evidence & confidence

The purchase size is modest relative to market cap; typical insider buys have limited immediate effect.

Market effects

Sector

None significant; the organ‑care device sector remains unchanged.

Regional

No broader regional effect.

Global

Limited to TransMedics investors.

Counterpoint

What could challenge this read

The buy could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Director
    David Weill

    Insider who purchased shares.

  • Company
    TransMedics Group, Inc.

    Medical technology firm focused on organ transplant devices.

Read at source← All news

Related articles

SEP 22
$TMDXMed

TransMedics Group (TMDX) Has A Fresh Update, What Are Investors Weighing?

TransMedics Group (TMDX) appointed Fernando Araujo as CFO and reaffirmed its 2026 revenue guidance of $737M-$757M. The stock has seen volatility, down 7.9% in the past month but up 18.2% over 90 days. Analysts estimate a fair value of $97.30, suggesting a 10.3% undervaluation. Expansion into new organ types and product launches could drive growth, but risks include international expansion and regulatory support.

simplywall.st2 min
SEP 15
$TMDXMed

2 Stocks Down 28% and 34% to Buy and Hold

TransMedics Group (TMDX) and SoFi Technologies (SOFI) have seen significant stock declines. TMDX's revenue grew 21% YoY to $189.9M, but profits fell 52%. SOFI's revenue rose 43% to $1.2B, with net income up 61%. Both face near-term challenges but are seen as long-term opportunities.

aol.com3 min
AUG 5
$TMDXMed

Why TransMedics Stock Is Sinking Today

TransMedics (NASDAQ: TMDX) shares fell about 8% after its Q2 results. The company reported 21% sales growth, but adjusted net income dropped from $35M in Q2 last year to $16M this year, below expectations. Management said about $19M of the change reflected spending on a next-gen kidney OCS, clinical programs, and a manufacturing plant in Italy.

yahoo.com4 min
AUG 4
$TMDXHighAI 9/10

TransMedics Reports Second Quarter 2026 Financial Results

TransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.

prnewswire.com6 min
AUG 4
$TMDXMed

TransMedics Reports Second Quarter 2026 Financial Results

TransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and

SEC EDGAR 8-K4 min